![Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model](https://www.mdpi.com/cells/cells-12-00507/article_deploy/html/images/cells-12-00507-g009.png)
Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model
PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease | PLOS Medicine
Targeting CD28, CTLA-4 and PD-L1 Costimulation Differentially Controls Immune Synapses and Function of Human Regulatory and Conventional T-Cells | PLOS ONE
![Frontiers | CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy Frontiers | CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy](https://www.frontiersin.org/files/MyHome%20Article%20Library/410152/410152_Thumb_400.jpg)
Frontiers | CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
Robert Plenge on Twitter: "Accordingly, interventions that interfere with co-stimulation of CD4+ T cells by APCs – CTLA4-Ig, which prevents the interaction between CD80/86 (on APCs) and CD28 (on T cells) –
![Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model](https://www.mdpi.com/cells/cells-12-00507/article_deploy/html/images/cells-12-00507-g001.png)
Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model
![RCSB PDB - 7LM9: Crystal structure of SARS-CoV spike protein receptor-binding domain in complex with a cross-neutralizing antibody CV38-142 Fab isolated from COVID-19 patient RCSB PDB - 7LM9: Crystal structure of SARS-CoV spike protein receptor-binding domain in complex with a cross-neutralizing antibody CV38-142 Fab isolated from COVID-19 patient](https://cdn.rcsb.org/images/structures/7lm9_model-1.jpeg)